Showing 91-100 of 353 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Studies of Promising Functional Endpoints in Eyes of Patients with Diabetes (Protocols AR and AS ) | Jaeb Center for Health Research | Adam Glassman | Improving Lives | 01-May-2026 to 30-April-2030 | $1.035.583,00 |
| JDRF T1D Coordinating Center | Jaeb Center for Health Research | Judy Sibayan | Transportfolio | 01-August-2019 to 31-August-2027 | $2.914.531,01 |
| A Novel Bifunctional Biologic for Type 1 Diabetes | Johns Hopkins University | Giorgio Raimondi | Cures | 01-February-2025 to 31-January-2028 | $995.376,00 |
| Exploring Immunologic Mechanisms of Indirect (Encapsulated) Islet Graft Rejection | Johns Hopkins University | Joshua Doloff | Cures | 01-November-2025 to 31-October-2028 | $1.125.000,00 |
| Harnessing Real-World Data to Advance Cardiorenal Therapies in Type 1 Diabetes | Johns Hopkins University | Jung-Im Shin | Improving Lives | 01-July-2026 to 30-June-2028 | $599.916,46 |
| REGULATORY ROLE OF CADM1 DURING AUTOIMMUNE DIABETES | Johns Hopkins University | Matthew Poy | Cures | 01-December-2024 to 30-November-2027 | $900.000,00 |
| Towards FDA approval of Autonomous AI for diabetic retinopathy screening in youth | Johns Hopkins University | Risa Wolf | Improving Lives | 01-January-2023 to 31-December-2026 | $637.547,20 |
| Effectiveness and safety of sotagliflozin in slowing kidney function decline in persons with type 1 diabetes and moderate to severe diabetic kidney disease: The SUGARNSALT Trial | Joslin Diabetes Center Inc. | Alessandro Doria | Improving Lives | 01-January-2024 to 31-December-2028 | $8.913.450,00 |
| Study of ALDH3B2 as a regulator of pancreatic beta cell neogenesis | Joslin Diabetes Center Inc. | Jian Li | Cures | 01-August-2023 to 31-July-2026 | $212.708,89 |
| Validation of a new approach for cardiovascular disease risk stratification and therapeutic targeting in T1D | Joslin Diabetes Center Inc. | Myra Lipes | Improving Lives | 01-September-2023 to 30-June-2027 | $1.341.376,33 |